Skip to content

The Treatment Efficacy of Prolotherapy in Bladder Voiding Dysfunction

The Treatment Efficacy of Prolotherapy in Bladder Voiding Dysfunction

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05485142
Enrollment
80
Registered
2022-08-03
Start date
2019-05-01
Completion date
2024-06-30
Last updated
2023-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder, Underactive Bladder

Keywords

neural prolotherapy, detrusor underactivity, overactive bladder

Brief summary

Voiding dysfunction including overactive bladder, underactive bladder, and neuropathic bladder. Voiding dysfunction has a great impact on life quality, especially in the elderly society. The current medication for overactive bladder has limited efficacy and the patient easily to dropout the medication because of its side-effects. The underactive bladder is a new entity of voiding dysfunction, its optimal is still unknown. Sacral neuromodulation(SNM) and posterior tibial nerve stimulation(PTNS) have been applied for both overactive bladder and underactive bladder treatment and the results is promising, but the equipment of SNM or PTNS is not available in most places. Prolotherapy using glucose local injection causing inflammatory reaction to stimulate cytokine and growth factors release. Investigators combined the concepts of posterior tibial nerve stimulation and prolotherapy to treat voiding dysfunction. Investigators anticipate it maybe a new promising treatment for voiding dysfunction.

Detailed description

Inclusion criteria:1. Adults over 20 years-old. 2. The patient who meets the diagnostic criteria of overactive bladder or underactive bladder. 3. The patient who capable to complete 3-days voiding diary and the questionnaire. Exclusion criteria: 1. The patient has severe stress urinary incontinence, severe pelvic organ prolapse, acute urinary tract infection, urolithiasis, or urinary tract malignancy. 2. The patient who has active skin disease on legs or not suitable for leg local injection. 3. Pregnant women. Method: 40 overactive bladder patients and 40 underactive bladder patients. The patients will receive 5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks, then the patients will be followed up once-a-month for 3 months. OverActive Bladder Symptom Score(OABSS), Core Lower Urinary Tract Symptom score(CLSS) questionnaire, 3-days voiding diary, and urine nerve growth factor are used for assessment.

Interventions

PROCEDUREprolotherapy

5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.

Sponsors

Taichung Armed Forces General Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adults over 20 years-old. 2. The patient who meets the diagnostic criteria of overactive bladder or underactive bladder. 3. The patient who capable to complete 3-days voiding diary and the questionnaire.

Exclusion criteria

1. Severe stress urinary incontinence or severe pelvic organ prolapse. 2. Acute urinary tract infection. 3. Active hematuria, urolithiasis, or neoplasm of urinary tract. 4. Acute skin lesion over the ankle injection site or the patient who could not tolerate ankle injection. 5. Pregnant women.

Design outcomes

Primary

MeasureTime frameDescription
Overactive Bladder Symptom ScoreWeek 0The improvement of overactive bladder symptom score (OABSS), OABSS ranged from 0 to 15, the higher score means more severity of overactive bladder.

Secondary

MeasureTime frameDescription
Cystometric bladder capacityWeek0Cystometric bladder capacity: the volume of water instilled into bladder while performing cystometry examination.

Other

MeasureTime frameDescription
The improvement of Patient Perception of Bladder Condition (PPBC)Week 0The PPBC measures the patients' perception of their urinary (bladder) problems. Ranged from 1 to 6. The core 1 means no bother from bladder condition, higher score means more bother form bladder condition.
The improvement of Patient Perception of Bladder ConditionWeek1The PPBC measures the patients' perception of their urinary (bladder) problems. Ranged from 1 to 6. The core 1 means no bother from bladder condition, higher score means more bother form bladder condition.

Countries

Taiwan

Contacts

Primary ContactJing-dung Shen, MD
jdwhydo@gmail.com+886958878129

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026